A Phase II Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination With Docetaxel in Advanced Breast Cancer.

Trial Profile

A Phase II Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination With Docetaxel in Advanced Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs Custirsen (Primary) ; Docetaxel
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Mar 2010 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
    • 16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 May 2008 Interim results data have been reported, according to a Sonus Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top